SG11201906943VA - Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use - Google Patents

Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Info

Publication number
SG11201906943VA
SG11201906943VA SG11201906943VA SG11201906943VA SG11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA SG 11201906943V A SG11201906943V A SG 11201906943VA
Authority
SG
Singapore
Prior art keywords
peptide
international
elastin
human
lock
Prior art date
Application number
SG11201906943VA
Other languages
English (en)
Inventor
Gert Wensvoort
Original Assignee
Biotempt Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotempt Bv filed Critical Biotempt Bv
Publication of SG11201906943VA publication Critical patent/SG11201906943VA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201906943VA 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use SG11201906943VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17154889 2017-02-06
PCT/EP2018/052822 WO2018141969A1 (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use

Publications (1)

Publication Number Publication Date
SG11201906943VA true SG11201906943VA (en) 2019-08-27

Family

ID=57995050

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906943VA SG11201906943VA (en) 2017-02-06 2018-02-05 Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
SG11201906939XA SG11201906939XA (en) 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201906939XA SG11201906939XA (en) 2017-02-06 2018-02-05 Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Country Status (8)

Country Link
US (4) US20200087374A1 (https=)
EP (3) EP3577462B1 (https=)
JP (2) JP7438757B2 (https=)
AU (2) AU2018216033B2 (https=)
CA (2) CA3051293A1 (https=)
ES (1) ES2927977T3 (https=)
SG (2) SG11201906943VA (https=)
WO (2) WO2018141970A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6982395B2 (ja) * 2017-03-16 2021-12-17 三洋化成工業株式会社 インターロイキン１０の産生量増加剤
WO2019104391A1 (en) * 2017-12-01 2019-06-06 St Vincent's Institute Of Medical Research Type 1 diabetes treatment
CA3149581A1 (en) * 2019-08-30 2021-03-04 Gert Wensvoort Q-er peptide
JP6895148B1 (ja) * 2020-03-31 2021-06-30 クラシエホールディングス株式会社 冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定用マーカー、冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定する判定方法、及び冷え保有者における冷えの原因が、腎機能低下、水分代謝異常又は副腎疲労にあることを判定するための判定用キット
CN117106029A (zh) * 2020-06-08 2023-11-24 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
AU2021356578A1 (en) * 2020-10-08 2023-05-11 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
CN112345770A (zh) * 2020-11-06 2021-02-09 苏州大学附属第一医院 弹性蛋白降解肽作为腹膜透析患者血管钙化标志物的应用
KR102718109B1 (ko) * 2021-10-01 2024-10-17 (주)케어젠 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도
JP2024537244A (ja) * 2021-10-05 2024-10-10 バイオテンプト ベー．フェー 好ましくは血糖コントロールと組み合わせた、血管新生コントロール
AU2023308137A1 (en) 2022-07-12 2025-01-30 Biotempt B.V. Treating conditions with hypoglycemia associated with hyperinsulinemia.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
EP1578352A2 (en) * 2002-03-27 2005-09-28 University of Utah Research Foundation Elastin prevents occlusion of body vessels by vascular smooth muscle cells
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
GB0412174D0 (en) 2004-06-01 2004-06-30 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
JP2015507193A (ja) * 2012-02-01 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性結合物の結合パートナーを検出するための方法
EP2626704B1 (en) * 2012-02-08 2015-11-18 Mehmet Ali Soylemez Diagnosis of pancreatic diabetes in patients with normal blood leucocyte counts using procalcitonin
EP2836841B1 (en) * 2012-04-12 2022-01-05 B.R.A.H.M.S GmbH Prognosis of adverse events in patients with suspected chronic heart failure
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2897327A1 (en) * 2013-01-08 2014-07-17 Sphingotec Gmbh Fasting levels of growth hormone as a predictive marker of cardiovascular risk
WO2014145836A1 (en) * 2013-03-15 2014-09-18 Health Diagnostic Laboratory, Inc. Method of generating an index score for mbl deficiency to predict cardiodiabetes risk
CN104371003B (zh) 2013-08-15 2025-09-02 上海市第一人民医院 预防和治疗炎症的小分子多肽及其应用
WO2015140317A1 (en) * 2014-03-21 2015-09-24 Sanofi New markers for the assessment of the risk for development of a cardiovascular disorder

Also Published As

Publication number Publication date
EP3577462B1 (en) 2024-04-17
US20220009988A1 (en) 2022-01-13
AU2018215245B2 (en) 2024-07-11
CA3051293A1 (en) 2018-08-09
AU2018215245A1 (en) 2019-07-25
CA3049738A1 (en) 2018-08-09
EP4421088A3 (en) 2024-12-04
EP3577462A1 (en) 2019-12-11
WO2018141970A1 (en) 2018-08-09
AU2018216033A1 (en) 2019-08-15
WO2018141969A1 (en) 2018-08-09
ES2927977T3 (es) 2022-11-14
JP2024056838A (ja) 2024-04-23
US20200087374A1 (en) 2020-03-19
JP2020507623A (ja) 2020-03-12
US20250123275A1 (en) 2025-04-17
EP4421088A2 (en) 2024-08-28
EP3570875A1 (en) 2019-11-27
SG11201906939XA (en) 2019-08-27
JP7438757B2 (ja) 2024-02-27
EP3577462C0 (en) 2024-04-17
AU2018216033B2 (en) 2021-10-07
US20240027431A1 (en) 2024-01-25
EP3570875B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
SG11201906943VA (en) Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811432WA (en) Rna for cancer therapy
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201903282TA (en) Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201807912SA (en) Vaccine against rsv
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201901411VA (en) Conditionally active polypeptides and methods of generating them
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201809229VA (en) Pharmaceutical composition
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201810853UA (en) Anti-tnfrsf25 antibodies
SG11201908393YA (en) Modulators of pcsk9 expression